Literature DB >> 12788530

Cicatricial pemphigoid sera specifically react with the most C-terminal portion of BP180.

Jee Bum Lee1, Yuanlin Liu, Takashi Hashimoto.   

Abstract

BACKGROUND: cicatricial pemphigoid and bullous pemphigoid are characterized by circulating autoantibodies to the hemidesmosomal protein, BP180. Different clinical features between cicatricial pemphigoid and bullous pemphigoid appear to correlate with distinct target epitopes on BP180. Previous studies demonstrated that the majority of bullous pemphigoid sera react with immunodominant membrane-proximal non-collagenous domain (NC16a) on the extracellular portion of BP180, whereas cicatricial pemphigoid antibodies are directed to the C-terminal domains of BP180. However, the fine sites within the C-terminal domain of BP180 recognized by autoantibodies in patients with cicatricial pemphigoid and bullous pemphigoid have not yet been clearly elucidated.
OBJECTIVES: the aim of the present study was to analyze the fine specificity of the reactivity within the C-terminal domain of BP180 for the autoantibodies in sera from patients with cicatricial pemphigoid, and to compare the reactivity with that of bullous pemphigoid sera. METHODS AND
RESULTS: we generated three recombinant proteins with 101 amino acids, which together cover the C-terminal domain of BP180. We confirmed that cicatricial pemphigoid sera mainly react with most C-terminal portion, whereas bullous pemphigoid sera react with more N-terminal domains.
CONCLUSION: this study implicated that autoantibodies of sera from patients with cicatricial pemphigoid and bullous pemphigoid reacted differently within C-terminal domain of BP180.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12788530     DOI: 10.1016/s0923-1811(03)00035-5

Source DB:  PubMed          Journal:  J Dermatol Sci        ISSN: 0923-1811            Impact factor:   4.563


  7 in total

1.  Anti-BP180-type mucous membrane pemphigoid immunoglobulin G shows heterogeneity of internalization of BP180/collagen XVII into keratinocyte cytoplasm.

Authors:  Akiko Imanishi; Hisayoshi Imanishi; Sho Hiroyasu; Toshiyuki Ozawa; Hiroshi Koga; Norito Ishii; Yasuo Kitajima; Takashi Hashimoto; Daisuke Tsuruta
Journal:  Med Mol Morphol       Date:  2015-12-10       Impact factor: 2.309

Review 2.  [Mucous membrane pemphigoid].

Authors:  M M Holtsche; D Zillikens; E Schmidt
Journal:  Hautarzt       Date:  2018-01       Impact factor: 0.751

Review 3.  Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid.

Authors:  Kaisa Tasanen; Outi Varpuluoma; Wataru Nishie
Journal:  Front Immunol       Date:  2019-06-04       Impact factor: 8.786

Review 4.  Lichen Planus Pemphigoides: From Lichenoid Inflammation to Autoantibody-Mediated Blistering.

Authors:  Franziska Hübner; Ewan A Langan; Andreas Recke
Journal:  Front Immunol       Date:  2019-07-02       Impact factor: 7.561

Review 5.  Oral Lesions in Autoimmune Bullous Diseases: An Overview of Clinical Characteristics and Diagnostic Algorithm.

Authors:  Hanan Rashid; Aniek Lamberts; Gilles F H Diercks; Hendri H Pas; Joost M Meijer; Maria C Bolling; Barbara Horváth
Journal:  Am J Clin Dermatol       Date:  2019-12       Impact factor: 7.403

Review 6.  Type XVII collagen: Relevance of distinct epitopes, complement-independent effects, and association with neurological disorders in pemphigoid disorders.

Authors:  Bianca Opelka; Enno Schmidt; Stephanie Goletz
Journal:  Front Immunol       Date:  2022-08-10       Impact factor: 8.786

7.  European Guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology - Part II.

Authors:  E Schmidt; H Rashid; A V Marzano; A Lamberts; G Di Zenzo; G F H Diercks; S Alberti-Violetti; R J Barry; L Borradori; M Caproni; B Carey; M Carrozzo; G Cianchini; A Corrà; F G Dikkers; C Feliciani; G Geerling; G Genovese; M Hertl; P Joly; J M Meijer; V Mercadante; D F Murrell; M Ormond; H H Pas; A Patsatsi; S Rauz; B D van Rhijn; M Roth; J Setterfield; D Zillikens; G Zambruno; B Horváth; F Caux
Journal:  J Eur Acad Dermatol Venereol       Date:  2021-07-26       Impact factor: 6.166

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.